DUBLIN – Pierre Fabre SA is paying Array Biopharma Inc. $30 million up front plus up to $425 million more in milestones for European, Asian and Latin American rights to its phase III Mek inhibitor binimetinib and its phase III BRAF inhibitor encorafenib, thereby cleaning up the fallout from Novartis AG's purchase of Glaxosmithkline plc's oncology business.
